Market attractiveness remains moderate; the niche therapeutic indication for chemotherapy‑induced nausea and AIDS‑related anorexia sustains a steady revenue stream, yet growth is constrained by limited payer reimbursement and the emergence of alternative cannabinoids. Competitive intensity is low to moderate, with a handful of generic manufacturers and a single branded player (Marinol) dominating pricing power; however, upcoming biosimilar entrants could erode margins. The long‑term outlook is cautiously optimistic: regulatory pathways are stabilizing, and expanding clinical evidence may unlock new label expansions, supporting a CAGR of 4‑5% through 2035. Innovation is incremental, focused on novel delivery systems (e.g., oral sprays, sublingual tablets) and formulation refinements that improve bioavailability. Demand–supply balance is currently tight but manageable; raw cannabis‑derived Δ9‑THC supplies are secure, yet any disruption in agricultural output could pressure pricing. Key risk factors include stringent FDA scrutiny, potential schedule reclassification, and reimbursement volatility. Overall, the Dronabinol market outlook suggests steady, modest growth for investors with a tolerance for regulatory uncertainty.
